Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Women's Health | 21 | 2020 | 235 | 3.680 |
Why?
|
| Cognition | 17 | 2019 | 551 | 1.890 |
Why?
|
| Aging | 9 | 2016 | 938 | 1.800 |
Why?
|
| Estrogen Replacement Therapy | 15 | 2017 | 195 | 1.470 |
Why?
|
| Estrogens, Conjugated (USP) | 12 | 2017 | 138 | 1.430 |
Why?
|
| Postmenopause | 20 | 2019 | 427 | 1.220 |
Why?
|
| Cognition Disorders | 11 | 2019 | 370 | 1.080 |
Why?
|
| Quality of Life | 13 | 2016 | 961 | 1.040 |
Why?
|
| Dementia | 8 | 2019 | 245 | 0.970 |
Why?
|
| Hormone Replacement Therapy | 6 | 2019 | 89 | 0.930 |
Why?
|
| Disability Evaluation | 3 | 2020 | 238 | 0.930 |
Why?
|
| Activities of Daily Living | 7 | 2020 | 258 | 0.920 |
Why?
|
| Geriatric Assessment | 3 | 2020 | 388 | 0.850 |
Why?
|
| Medroxyprogesterone Acetate | 8 | 2017 | 100 | 0.760 |
Why?
|
| Female | 52 | 2020 | 20261 | 0.760 |
Why?
|
| Memory | 7 | 2019 | 191 | 0.720 |
Why?
|
| Health Status | 11 | 2016 | 402 | 0.670 |
Why?
|
| Humans | 59 | 2020 | 32798 | 0.630 |
Why?
|
| Aged | 42 | 2020 | 10538 | 0.620 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2005 | 54 | 0.610 |
Why?
|
| Diabetic Neuropathies | 1 | 2019 | 26 | 0.600 |
Why?
|
| Aged, 80 and over | 14 | 2020 | 4032 | 0.590 |
Why?
|
| Neuralgia | 1 | 2019 | 47 | 0.580 |
Why?
|
| Affect | 3 | 2018 | 70 | 0.570 |
Why?
|
| United States | 15 | 2020 | 4108 | 0.520 |
Why?
|
| Motor Activity | 3 | 2016 | 327 | 0.490 |
Why?
|
| Neuropsychological Tests | 11 | 2019 | 363 | 0.490 |
Why?
|
| Polysomnography | 1 | 2016 | 40 | 0.480 |
Why?
|
| Tamoxifen | 3 | 2012 | 59 | 0.480 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 57 | 0.470 |
Why?
|
| Independent Living | 1 | 2016 | 105 | 0.460 |
Why?
|
| Patient Dropouts | 1 | 2015 | 25 | 0.460 |
Why?
|
| Geriatrics | 1 | 2015 | 85 | 0.440 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2019 | 1462 | 0.440 |
Why?
|
| Patient Compliance | 1 | 2015 | 218 | 0.400 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2010 | 35 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 532 | 0.390 |
Why?
|
| Depression | 6 | 2012 | 448 | 0.390 |
Why?
|
| Cardiovascular Diseases | 4 | 2018 | 1140 | 0.380 |
Why?
|
| Middle Aged | 28 | 2020 | 12125 | 0.380 |
Why?
|
| Psychotic Disorders | 1 | 2012 | 11 | 0.380 |
Why?
|
| Schizophrenia | 1 | 2012 | 32 | 0.370 |
Why?
|
| Antipsychotic Agents | 1 | 2012 | 28 | 0.370 |
Why?
|
| Adaptation, Psychological | 3 | 2019 | 138 | 0.370 |
Why?
|
| Estrogens | 6 | 2013 | 169 | 0.350 |
Why?
|
| Medroxyprogesterone | 2 | 2017 | 12 | 0.350 |
Why?
|
| Breast Neoplasms | 4 | 2012 | 754 | 0.350 |
Why?
|
| Women's Health Services | 2 | 2013 | 10 | 0.340 |
Why?
|
| Health Surveys | 3 | 2016 | 200 | 0.340 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 162 | 0.330 |
Why?
|
| Cohort Studies | 7 | 2020 | 1844 | 0.330 |
Why?
|
| Progesterone Congeners | 3 | 2006 | 18 | 0.310 |
Why?
|
| Particulate Matter | 2 | 2020 | 28 | 0.290 |
Why?
|
| Risk Factors | 11 | 2020 | 3974 | 0.280 |
Why?
|
| Environmental Exposure | 2 | 2020 | 89 | 0.270 |
Why?
|
| Alzheimer Disease | 3 | 2020 | 302 | 0.260 |
Why?
|
| Proportional Hazards Models | 5 | 2018 | 764 | 0.250 |
Why?
|
| Memory Disorders | 2 | 2017 | 54 | 0.250 |
Why?
|
| Training Support | 1 | 2006 | 5 | 0.250 |
Why?
|
| Research Support as Topic | 1 | 2006 | 26 | 0.240 |
Why?
|
| Incidence | 5 | 2019 | 1238 | 0.240 |
Why?
|
| Double-Blind Method | 8 | 2019 | 525 | 0.230 |
Why?
|
| Faculty, Medical | 1 | 2006 | 77 | 0.230 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2005 | 95 | 0.220 |
Why?
|
| Psychometrics | 4 | 2012 | 137 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 111 | 0.200 |
Why?
|
| Factor Analysis, Statistical | 3 | 2012 | 76 | 0.200 |
Why?
|
| Sickness Impact Profile | 1 | 2003 | 35 | 0.190 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 767 | 0.190 |
Why?
|
| Dietary Supplements | 3 | 2019 | 187 | 0.190 |
Why?
|
| Health Services Research | 1 | 2003 | 81 | 0.190 |
Why?
|
| Clinical Trials as Topic | 3 | 2013 | 307 | 0.180 |
Why?
|
| Self-Help Devices | 1 | 2020 | 8 | 0.170 |
Why?
|
| Accidents, Home | 1 | 2020 | 17 | 0.170 |
Why?
|
| Environment Design | 1 | 2020 | 18 | 0.170 |
Why?
|
| Cause of Death | 2 | 2018 | 240 | 0.160 |
Why?
|
| Finasteride | 2 | 2012 | 4 | 0.160 |
Why?
|
| Brain | 2 | 2020 | 946 | 0.160 |
Why?
|
| Housing | 1 | 2020 | 65 | 0.160 |
Why?
|
| Magnesium | 1 | 2019 | 30 | 0.160 |
Why?
|
| Self Care | 2 | 2016 | 144 | 0.160 |
Why?
|
| Cacao | 1 | 2019 | 4 | 0.150 |
Why?
|
| Risk | 5 | 2017 | 315 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2017 | 3438 | 0.150 |
Why?
|
| Vitamins | 1 | 2019 | 73 | 0.150 |
Why?
|
| Plant Extracts | 1 | 2019 | 61 | 0.150 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 1307 | 0.150 |
Why?
|
| Survival Analysis | 2 | 2018 | 486 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2019 | 199 | 0.140 |
Why?
|
| Depressive Disorder | 1 | 2018 | 77 | 0.130 |
Why?
|
| Risk Assessment | 2 | 2018 | 1460 | 0.130 |
Why?
|
| Diet | 1 | 2019 | 390 | 0.130 |
Why?
|
| Androgens | 1 | 2017 | 28 | 0.130 |
Why?
|
| Predictive Value of Tests | 2 | 2018 | 887 | 0.130 |
Why?
|
| Testosterone | 1 | 2017 | 48 | 0.130 |
Why?
|
| Caffeine | 1 | 2016 | 29 | 0.130 |
Why?
|
| Mortality | 1 | 2017 | 124 | 0.130 |
Why?
|
| Age Factors | 3 | 2005 | 1197 | 0.130 |
Why?
|
| Placebos | 3 | 2007 | 63 | 0.120 |
Why?
|
| Longitudinal Studies | 6 | 2020 | 779 | 0.120 |
Why?
|
| Decision Making, Organizational | 1 | 2016 | 4 | 0.120 |
Why?
|
| Oximetry | 1 | 2016 | 31 | 0.120 |
Why?
|
| Ethnic Groups | 3 | 2018 | 474 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 835 | 0.120 |
Why?
|
| Interdisciplinary Communication | 1 | 2016 | 57 | 0.120 |
Why?
|
| Automobile Driving | 1 | 2015 | 26 | 0.120 |
Why?
|
| Male | 9 | 2019 | 19641 | 0.120 |
Why?
|
| Prostatic Neoplasms | 2 | 2012 | 476 | 0.110 |
Why?
|
| Prospective Studies | 7 | 2020 | 2327 | 0.110 |
Why?
|
| Life Style | 2 | 2016 | 407 | 0.110 |
Why?
|
| Demography | 1 | 2015 | 110 | 0.110 |
Why?
|
| Burnout, Professional | 1 | 2016 | 53 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 2 | 2012 | 24 | 0.110 |
Why?
|
| Health Status Indicators | 1 | 2015 | 74 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 308 | 0.110 |
Why?
|
| Adult | 5 | 2012 | 9560 | 0.110 |
Why?
|
| Research Design | 4 | 2004 | 331 | 0.110 |
Why?
|
| Progestins | 2 | 2005 | 22 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2016 | 171 | 0.110 |
Why?
|
| Sampling Studies | 2 | 2003 | 44 | 0.100 |
Why?
|
| Hysterectomy | 1 | 2013 | 49 | 0.100 |
Why?
|
| Refusal to Participate | 1 | 2013 | 4 | 0.100 |
Why?
|
| Population Surveillance | 2 | 2003 | 128 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 58 | 0.090 |
Why?
|
| Focus Groups | 1 | 2012 | 128 | 0.090 |
Why?
|
| Heart Failure | 1 | 2018 | 695 | 0.090 |
Why?
|
| Patient Selection | 1 | 2013 | 281 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2012 | 881 | 0.090 |
Why?
|
| Learning | 1 | 2011 | 80 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 160 | 0.080 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 23 | 0.070 |
Why?
|
| Bone Density Conservation Agents | 1 | 2008 | 23 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 599 | 0.070 |
Why?
|
| Hot Flashes | 2 | 2005 | 46 | 0.070 |
Why?
|
| Vitamin D | 1 | 2008 | 189 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2007 | 50 | 0.060 |
Why?
|
| North Carolina | 2 | 2012 | 1546 | 0.060 |
Why?
|
| Budgets | 1 | 2006 | 9 | 0.060 |
Why?
|
| Financing, Organized | 1 | 2006 | 14 | 0.060 |
Why?
|
| Benchmarking | 1 | 2006 | 25 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2006 | 43 | 0.060 |
Why?
|
| Program Evaluation | 1 | 2006 | 181 | 0.060 |
Why?
|
| Drug Labeling | 1 | 2005 | 3 | 0.060 |
Why?
|
| Norethindrone | 1 | 2005 | 2 | 0.060 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2005 | 29 | 0.060 |
Why?
|
| Drug Industry | 1 | 2005 | 17 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 51 | 0.060 |
Why?
|
| Osteoarthritis, Knee | 1 | 2005 | 81 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 2284 | 0.050 |
Why?
|
| Administration, Cutaneous | 1 | 2005 | 115 | 0.050 |
Why?
|
| Estradiol | 1 | 2005 | 121 | 0.050 |
Why?
|
| Menopause | 1 | 2005 | 97 | 0.050 |
Why?
|
| Attitude of Health Personnel | 1 | 2005 | 188 | 0.050 |
Why?
|
| Linear Models | 3 | 2012 | 445 | 0.050 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 1572 | 0.050 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 111 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2005 | 271 | 0.050 |
Why?
|
| Physicians | 1 | 2005 | 165 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2003 | 214 | 0.050 |
Why?
|
| Continental Population Groups | 2 | 2018 | 236 | 0.040 |
Why?
|
| Coronary Artery Disease | 1 | 2003 | 413 | 0.040 |
Why?
|
| Catechol O-Methyltransferase | 1 | 2019 | 14 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 2002 | 280 | 0.040 |
Why?
|
| LDL-Receptor Related Proteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Membrane Transport Proteins | 1 | 2019 | 33 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2019 | 37 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 71 | 0.040 |
Why?
|
| Apolipoproteins E | 1 | 2019 | 87 | 0.040 |
Why?
|
| Time Factors | 2 | 2017 | 2183 | 0.030 |
Why?
|
| Socioeconomic Factors | 2 | 2013 | 436 | 0.030 |
Why?
|
| Mental Health | 2 | 2012 | 128 | 0.030 |
Why?
|
| Contraceptive Agents, Female | 1 | 2017 | 15 | 0.030 |
Why?
|
| Kidney Failure, Chronic | 1 | 2002 | 543 | 0.030 |
Why?
|
| Cerebrum | 1 | 2017 | 6 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2017 | 28 | 0.030 |
Why?
|
| Gels | 1 | 2017 | 32 | 0.030 |
Why?
|
| Neurites | 1 | 2017 | 8 | 0.030 |
Why?
|
| Receptors, AMPA | 1 | 2017 | 15 | 0.030 |
Why?
|
| Atrophy | 1 | 2017 | 46 | 0.030 |
Why?
|
| CA1 Region, Hippocampal | 1 | 2017 | 27 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 56 | 0.030 |
Why?
|
| Mental Recall | 1 | 2017 | 51 | 0.030 |
Why?
|
| Apolipoprotein E4 | 1 | 2017 | 57 | 0.030 |
Why?
|
| Reference Values | 1 | 2017 | 238 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 258 | 0.030 |
Why?
|
| African Americans | 2 | 2018 | 1424 | 0.030 |
Why?
|
| Professional Autonomy | 1 | 2016 | 6 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2016 | 23 | 0.030 |
Why?
|
| Organizational Culture | 1 | 2016 | 25 | 0.030 |
Why?
|
| Proxy | 1 | 2015 | 8 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2015 | 34 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2019 | 1066 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 726 | 0.030 |
Why?
|
| Statistics as Topic | 2 | 2004 | 104 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 219 | 0.030 |
Why?
|
| Research Subjects | 1 | 2013 | 19 | 0.020 |
Why?
|
| Social Support | 2 | 2003 | 183 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2003 | 288 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2013 | 467 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2012 | 180 | 0.020 |
Why?
|
| Mice | 1 | 2017 | 2511 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2011 | 195 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 783 | 0.020 |
Why?
|
| Neoplasms | 1 | 2017 | 761 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 565 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2007 | 1 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 163 | 0.020 |
Why?
|
| Fractures, Bone | 1 | 2008 | 161 | 0.020 |
Why?
|
| Animals | 1 | 2017 | 7569 | 0.010 |
Why?
|
| Progesterone | 1 | 2004 | 69 | 0.010 |
Why?
|
| Antidepressive Agents | 1 | 2004 | 74 | 0.010 |
Why?
|
| Income | 1 | 2003 | 67 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2003 | 72 | 0.010 |
Why?
|
| Data Collection | 1 | 2003 | 185 | 0.010 |
Why?
|
| Urinary Incontinence | 1 | 2003 | 48 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2003 | 158 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2004 | 622 | 0.010 |
Why?
|
| Sexual Behavior | 1 | 2003 | 125 | 0.010 |
Why?
|
| Sex Factors | 1 | 2003 | 675 | 0.010 |
Why?
|
| Health Behavior | 1 | 2003 | 234 | 0.010 |
Why?
|
| Prevalence | 1 | 2004 | 1002 | 0.010 |
Why?
|
| Exercise | 1 | 2004 | 679 | 0.010 |
Why?
|